Drugs

Articles

• amiodarone
  24 February 2005

  Definition: Amiodarone is a potent antiarrhythmic agent.
  Images
  Amiodarone-induced change in thyroid
  https://twitter.com/aakasharmand/status/727148670987149312
  cirrhosis and amiodarone
  https://twitter.com/CArnold_GI/status/735956508492615682
  Liver injury
  Amiodarone causes elevated liver enzymes in up to 30% of patients and steatohepatitis in 1–2% of patients.
  The majority of cases display liver enzyme abnormalities within 24 h of intravenous infusion.
  Even low oral dosing (200 (...)

• statins
  9 May 2005

  Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels.
  However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such (...)

• Sulindac
  31 May 2007

  Sulindac is a nonsteroidal anti-inflammatory drug.
  It has been reported to be effective in suppressing tumor growth through the induction of p21WAF1/cip1 in human, animal models of colon cancer and colon cancer cells.
  The efficiency of sulindac in the inhibition of cell proliferation (other than the induction of apoptosis) may be through the suppression of beta-catenin pathway in human breast and lung cancer cell (...)

• taxanes
  5 January 2006

  Definition : Taxanes are a class of diterpenes.
  Taxanes were originally identified from plants of the genus Taxus (yews), and feature a taxadiene core.
  Molecules as paclitaxel (Taxol) and docetaxel (Taxotere) are widely used as chemotherapy agents. cabazitaxel was FDA approved to treat hormone-refractory prostate cancer.
  Taxanes are important drugs in the treatment of ovarian and other cancers, but their efficacy is limited by intrinsic and acquired drug resistance.
  Resistance (...)

• artemisinins
  31 May 2006

  Combinations of an artemisinin with other antimalarial drugs are now recommended treatments for Plasmodium falciparum malaria in most endemic areas.
  Several individual molecules have been proposed as targets for artemisinins, in addition to the idea that artemisinins might have many targets at the same time.
  Artemisinins could inhibit the parasite-encoded sarco-endoplasmic reticulum Ca(2+)-ATPase (SERCA) PfATP6. A polymorphism in the gene encoding PfATP6 is associated with in vitro (...)

• acetaminophen
  30 January 2006

  Acetaminophen (Tylenol)

• sunitinib
  2 June 2009

  Definition: Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTKs) inhibitor (multiRTKs inhibitors).
  Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
  The concept was of a ATP analogue that would compete with ATP for binding to the catalytic site of receptor tyrosine kinases. This concept led (...)

• asparginase
  12 March 2006

  Asparaginase is an enzyme that has been purified from E. coli and Erwinia carotovora. It acts by deaminating extracellular L-asparagine, an amino acid that appears to be essential for protein synthesis by some tumour cells lacking adequate levels of asparagine synthetase.
  Asparaginase from Erwinia carotovora is serologically and biochemically distinct from asparaginase from E. coli, although its antineoplastic activity and toxicity is similar. Asparaginase is usually considered to be cell (...)

• platinum
  12 June 2005

  The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.
  Although carboplatin—a second-generation analogue that is safer but shows a similar spectrum of activity to cisplatin—was introduced in the 1980s, the pace of further improvements slowed for many years.
  However, in the past several years interest in platinum drugs has increased.
  Key developments include the (...)

• methotrexate
  28 November 2005

  MTX

0 | 10 | 20 | 30